{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:43:40Z","timestamp":1790747020720,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"35","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>In the STEP-HFpEF trial programme, treatment with semaglutide resulted in multiple beneficial effects in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). Efficacy may vary according to baseline diuretic use, and semaglutide treatment could modify diuretic dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this pre-specified analysis of pooled data from the STEP-HFpEF and STEP-HFpEF-DM trials (n = 1145), which randomized participants with HFpEF and body mass index \u2265 30 kg\/m2 to once weekly semaglutide 2.4 mg or placebo for 52 weeks, we examined whether efficacy and safety endpoints differed by baseline diuretic use, as well as the effect of semaglutide on loop diuretic use and dose changes over the 52-week treatment period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, across no diuretic (n = 220), non-loop diuretic only (n = 223), and loop diuretic [&amp;lt;40 (n = 219), 40 (n = 309), and &amp;gt;40 (n = 174) mg\/day furosemide equivalents] groups, there was progressively higher prevalence of hypertension and atrial fibrillation; and greater severity of obesity and heart failure. Over 52 weeks of treatment, semaglutide had a consistent beneficial effect on change in body weight across diuretic use categories (adjusted mean difference vs. placebo ranged from \u22128.8% [95% confidence interval (CI) \u221210.3, \u22126.3] to \u22126.9% [95% CI \u22129.1, \u22124.7] from no diuretics to the highest loop diuretic dose category; interaction P = .39). Kansas City Cardiomyopathy Questionnaire clinical summary score improvement was greater in patients on loop diuretics compared to those not on loop diuretics (adjusted mean difference vs. placebo: +9.3 [6.5; 12.1] vs. +4.7 points [1.3, 8.2]; P = .042). Semaglutide had consistent beneficial effects on all secondary efficacy endpoints (including 6 min walk distance) across diuretic subgroups (interaction P = .24\u2013.92). Safety also favoured semaglutide vs. placebo across the diuretic subgroups. From baseline to 52 weeks, loop diuretic dose decreased by 17% in the semaglutide group vs. a 2.4% increase in the placebo group (P &amp;lt; .0001). Semaglutide (vs. placebo) was more likely to result in loop diuretic dose reduction (odds ratio [OR] 2.67 [95% CI 1.70, 4.18]) and less likely dose increase (OR 0.35 [95% CI 0.23, 0.53]; P &amp;lt; .001 for both) from baseline to 52 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with obesity-related HFpEF, semaglutide improved heart failure-related symptoms and physical limitations across diuretic use subgroups, with more pronounced benefits among patients receiving loop diuretics at baseline. Reductions in weight and improvements in exercise function with semaglutide vs. placebo were consistent in all diuretic use categories. Semaglutide also led to a reduction in loop diuretic use and dose between baseline and 52 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>NCT04788511 and NCT04916470.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehae322","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:49:11Z","timestamp":1715597351000},"page":"3254-3269","source":"Crossref","is-referenced-by-count":94,"title":["Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials"],"prefix":"10.1093","volume":"45","author":[{"given":"Sanjiv J","family":"Shah","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Sharma","sequence":"additional","affiliation":[{"name":"Division of Cardiology, The Johns Hopkins University School of Medicine , Baltimore, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9375-0596","authenticated-orcid":false,"given":"Barry A","family":"Borlaug","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7683-4720","authenticated-orcid":false,"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Research Institute , Dallas, TX ,","place":["USA"]},{"name":"Department of Medicine, University of Mississippi , Jackson, MS ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Davies","sequence":"additional","affiliation":[{"name":"Diabetes Research Centre, University of Leicester , Leicester ,","place":["UK"]},{"name":"NIHR Leicester Biomedical Research Centre , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalane W","family":"Kitzman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sections on Cardiovascular Medicine and Geriatrics\/Gerontology, Wake Forest University School of Medicine , Winston-Salem, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C","family":"Petrie","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St Michael\u2019s Hospital, Unity Health Toronto, University of Toronto , Toronto, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shachi","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Saint Luke\u2019s Mid America Heart Institute , Kansas City, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaja M","family":"Chinnakondepalli","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Saint Luke\u2019s Mid America Heart Institute , Kansas City, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette N","family":"Einfeldt","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J","family":"Jensen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0258-7402","authenticated-orcid":false,"given":"Rabea","family":"Asleh","sequence":"additional","affiliation":[{"name":"Heart Institute, Hadassah University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem , Jerusalem ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuvia","family":"Ben-Gal","sequence":"additional","affiliation":[{"name":"Heart Failure Unit, Cardiology Department, Rabin Medical Center, Faculty of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3750-9789","authenticated-orcid":false,"given":"Mikhail N","family":"Kosiborod","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Saint Luke\u2019s Mid America Heart Institute , Kansas City, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"key":"2024092614155760800_ehae322-B1","doi-asserted-by":"publisher","first-page":"e45794","DOI":"10.7759\/cureus.45794","article-title":"A narrative review on the efficacy and safety of loop diuretics in patients with heart failure with reduced ejection fraction and preserved ejection fraction","volume":"15","author":"Pius","year":"2023","journal-title":"Cureus"},{"key":"2024092614155760800_ehae322-B2","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.123.066506","article-title":"Outpatient worsening among patients with mildly reduced and preserved ejection fraction heart failure in the DELIVER trial","volume":"148","author":"Chatur","year":"2023","journal-title":"Circulation"},{"key":"2024092614155760800_ehae322-B3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/ejhf.2376","article-title":"Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT","volume":"24","author":"Ferreira","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2024092614155760800_ehae322-B4","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1161\/CIRCULATIONAHA.123.066915","article-title":"Expanding the definition of worsening heart failure and recognizing the importance of outpatient escalation of oral diuretics","volume":"148","author":"Greene","year":"2023","journal-title":"Circulation"},{"key":"2024092614155760800_ehae322-B5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1001\/jamacardio.2017.5250","article-title":"Outpatient worsening heart failure as a target for therapy: a review","volume":"3","author":"Greene","year":"2018","journal-title":"JAMA Cardiology"},{"key":"2024092614155760800_ehae322-B6","doi-asserted-by":"publisher","first-page":"e017485","DOI":"10.1161\/JAHA.120.017485","article-title":"Recognizing the significance of outpatient worsening heart failure","volume":"9","author":"Khan","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2024092614155760800_ehae322-B7","doi-asserted-by":"publisher","first-page":"e016010","DOI":"10.1161\/JAHA.119.016010","article-title":"One-year mortality after intensification of outpatient diuretic therapy","volume":"9","author":"Madelaire","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2024092614155760800_ehae322-B8","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1161\/CIRCULATIONAHA.115.020729","article-title":"Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)","volume":"133","author":"Okumura","year":"2016","journal-title":"Circulation"},{"key":"2024092614155760800_ehae322-B9","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/ehf2.12677","article-title":"Outpatient treatment of worsening heart failure with intravenous and subcutaneous diuretics: a systematic review of the literature","volume":"7","author":"Wierda","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2024092614155760800_ehae322-B10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ejhf.3092","article-title":"Obesity in heart failure with preserved ejection fraction: insights from the REDUCE LAP-HF II trial","volume":"26","author":"Litwin","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2024092614155760800_ehae322-B11","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.mayocp.2023.07.008","article-title":"Obesity, cardiorenal comorbidities, and risk of hospitalization in patients with heart failure with preserved ejection fraction","volume":"98","author":"Morgen","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"2024092614155760800_ehae322-B12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cardfail.2019.09.015","article-title":"Adverse renal response to decongestion in the obese phenotype of heart failure with preserved ejection fraction","volume":"26","author":"Reddy","year":"2020","journal-title":"J Card Fail"},{"key":"2024092614155760800_ehae322-B13","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2024092614155760800_ehae322-B14","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2024092614155760800_ehae322-B15","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide and obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"2024092614155760800_ehae322-B16","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jchf.2023.05.010","article-title":"Design and baseline characteristics of STEP-HFpEF program evaluating semaglutide in patients with obesity HFpEF phenotype","volume":"11","author":"Kosiborod","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2024092614155760800_ehae322-B17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJM199808063390607","article-title":"Diuretic therapy","volume":"339","author":"Brater","year":"1998","journal-title":"N Engl J Med"},{"key":"2024092614155760800_ehae322-B18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/eurheartj\/ehr352","article-title":"The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities","volume":"33","author":"Pocock","year":"2011","journal-title":"Eur Heart J"},{"key":"2024092614155760800_ehae322-B19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"2024092614155760800_ehae322-B20","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"2024092614155760800_ehae322-B21","doi-asserted-by":"publisher","first-page":"F867","DOI":"10.1152\/ajprenal.00527.2014","article-title":"Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow","volume":"308","author":"Jensen","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"2024092614155760800_ehae322-B22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/cells13010065","article-title":"GLP1 receptor agonists-effects beyond obesity and diabetes","volume":"13","author":"Wilbon","year":"2023","journal-title":"Cells"},{"key":"2024092614155760800_ehae322-B23","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2337\/dc22-1889","article-title":"Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the STEP 1, 2, and 3 trials","volume":"46","author":"Heerspink","year":"2023","journal-title":"Diabetes Care"},{"key":"2024092614155760800_ehae322-B24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/ehjcvp\/pvad080","article-title":"FLOW trial stopped early due to evidence of renal protection with semaglutide","volume":"10","author":"Gragnano","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024092614155760800_ehae322-B25","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1001\/jamacardio.2023.1090","article-title":"Safety and efficacy of empagliflozin and diuretic use in patients with heart failure and preserved ejection fraction: a post hoc analysis of the EMPEROR-Preserved trial","volume":"8","author":"Butler","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2024092614155760800_ehae322-B26","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1177\/08971900231159739","article-title":"Impact of inpatient initiation of SGLT2 inhibitors on diuretic requirements in patients with heart failure","volume":"37","author":"Cavagnini","year":"2024","journal-title":"J Pharm Pract"},{"key":"2024092614155760800_ehae322-B27","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1093\/eurheartj\/ehad283","article-title":"Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial","volume":"44","author":"Chatur","year":"2023","journal-title":"Eur Heart J"},{"key":"2024092614155760800_ehae322-B28","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3179","article-title":"Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: insights from the VICTORIA trial","volume":"26","author":"Ezekowitz","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2024092614155760800_ehae322-B29","doi-asserted-by":"publisher","first-page":"e006597","DOI":"10.1161\/CIRCHEARTFAILURE.119.006597","article-title":"Reduced diuretic dose in patients treated with eplerenone","volume":"13","author":"Ferreira","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2024092614155760800_ehae322-B30","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1161\/CIRCULATIONAHA.120.047077","article-title":"Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF","volume":"142","author":"Jackson","year":"2020","journal-title":"Circulation"},{"key":"2024092614155760800_ehae322-B31","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/ejhf.1917","article-title":"Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis","volume":"22","author":"Kalogeropoulos","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2024092614155760800_ehae322-B32","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1177\/08971900231177202","article-title":"Sacubitril\/valsartan does not change the use and dose of loop diuretics in patients with heart failure with reduced ejection fraction","volume":"37","author":"Kido","year":"2024","journal-title":"J Pharm Pract"},{"key":"2024092614155760800_ehae322-B33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/ejhf.1402","article-title":"Reduced loop diuretic use in patients taking sacubitril\/valsartan compared with enalapril: the PARADIGM-HF trial","volume":"21","author":"Vardeny","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2024092614155760800_ehae322-B34","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1161\/CIRCULATIONAHA.120.047480","article-title":"Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF","volume":"142","author":"Docherty","year":"2020","journal-title":"Circulation"},{"key":"2024092614155760800_ehae322-B35","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/ejhf.1796","article-title":"Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry","volume":"22","author":"Kapelios","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2024092614155760800_ehae322-B36","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ahj.2012.08.019","article-title":"Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure","volume":"164","author":"Shah","year":"2012","journal-title":"Am Heart J"},{"key":"2024092614155760800_ehae322-B37","doi-asserted-by":"publisher","first-page":"e008293","DOI":"10.1161\/CIRCHEARTFAILURE.120.008293","article-title":"Association of hyper-polypharmacy with clinical outcomes in heart failure with preserved ejection fraction","volume":"14","author":"Minamisawa","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2024092614155760800_ehae322-B38","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1001\/jama.2022.23924","article-title":"Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial","volume":"329","author":"Mentz","year":"2023","journal-title":"JAMA"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehae322\/57567925\/ehae322.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/35\/3254\/59118076\/ehae322.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/35\/3254\/59118076\/ehae322.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T10:16:26Z","timestamp":1727345786000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/45\/35\/3254\/7670783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":38,"journal-issue":{"issue":"35","published-online":{"date-parts":[[2024,5,13]]},"published-print":{"date-parts":[[2024,9,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehae322","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9,14]]},"published":{"date-parts":[[2024,5,13]]}}}